Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy
Journal of Gastroenterology · 2024
DOI: 10.1007/s00535-024-02111-0 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Mitsuro Chiba und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Akita City Hospital, 4-30 Matsuoka-machi, Kawamoto, Akita City, 010-0933, Japan. mchibad00517@gmail.com. Hauptthemen laut MEDLINE: Infliximab, Colitis, Ulcerative, Gastrointestinal Agents. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Akita City Hospital, 4-30 Matsuoka-machi, Kawamoto, Akita City, 010-0933, Japan. mchibad00517@gmail.com.
- Division of Gastroenterology, Akita City Hospital, 4-30 Matsuoka-machi, Kawamoto, Akita City, 010-0933, Japan.
ORCID-Profile: Mitsuro Chiba
Zitieren
APA
Chiba, M., & Kimura, K. (2024). Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02111-0
Vancouver
Chiba M, Kimura K. Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02111-0
BibTeX
@article{Chiba2024,
author = {Chiba, Mitsuro and Kimura, Kazuya},
title = {Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy},
journal = {Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s00535-024-02111-0}
}
EUVIMED